Try the modernized beta website. Learn more about the modernization effort.
Working… Menu
Trial record 1 of 50 for:    arthritis innovation
Previous Study | Return to List | Next Study

Safety of F14 Following Total Knee Replacement

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04860635
Recruitment Status : Suspended (Study superseded by alternative Phase 3 trial)
First Posted : April 27, 2021
Last Update Posted : February 24, 2022
Information provided by (Responsible Party):
Arthritis Innovation Corporation

Brief Summary:
Open-label single-arm study in which all subjects receive F14 as part of a scheduled TKR and multimodal analgesia

Condition or disease Intervention/treatment Phase
Analgesia Drug: F14 (sustained release celecoxib) Phase 2 Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Open label
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label Safety Study of a Single Administration of F14 in Patients Undergoing Unilateral Total Knee Replacement
Estimated Study Start Date : January 2023
Estimated Primary Completion Date : May 2024
Estimated Study Completion Date : May 2024

Resource links provided by the National Library of Medicine

Drug Information available for: Celecoxib

Arm Intervention/treatment
Experimental: F14 (sustained release celecoxib)
Intra-articular F14 administration immediately following TKR surgery, and concurrent with multimodal standard of care analgesia
Drug: F14 (sustained release celecoxib)
Celecoxib in BEPO® drug delivery system

Primary Outcome Measures :
  1. Incidence and severity of treatment-emergent adverse events (TEAEs) [ Time Frame: From Day 0 to 12 months ]

Other Outcome Measures:
  1. NRS pain intensity [ Time Frame: From Day 1 to 3 months ]
    Numerical rating scale (NRS); 11-point scale ranges from '0' representing "no pain" to '10' representing "worst imaginable pain"

  2. Duration of need for walking aids [ Time Frame: From Day 1 to 3 months ]
  3. Proportion of subjects using concomitant analgesics at any timepoint [ Time Frame: From Day 1 to 3 months ]
  4. Celecoxib concentration in plasma [ Time Frame: At specified timepoints up to 3 months ]
    PK sub-study in 15 participants

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   45 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male and/or females indicated for primary, unilateral TKR
  2. Between 45-80 years of age
  3. Capable of giving signed informed consent
  4. Body Mass Index (BMI) ≤ 40 kg/m2
  5. Medically stable as determined by the Investigator, based on physical examination, clinical laboratory tests, and 12-lead ECG findings, as well as medical history from subject and pre-study source documents from other care providers
  6. Absence of fixed flexion deformity exceeding 15deg
  7. Absence of varus or valgus deformity exceeding 15deg
  8. Minimum pre-operative flexion arc of 100deg
  9. American Society of Anesthesiologists Physical Status Classification System (ASA-PSC) score ≤ 3
  10. Females of childbearing potential with a negative serum pregnancy test at screening or males with a partner that is of childbearing potential, who agree to employ adequate birth control measures for the full duration of the study
  11. Has undergone successful total knee replacement surgery, which in the opinion of the Investigator, will not affect the subject's study follow-up

Exclusion Criteria:

  1. Known allergy or hypersensitivity to active ingredient celecoxib, OR known allergy or hypersensitivity to sulfonamide antibiotics or sulfa containing drugs when an allergy to celecoxib is unknown
  2. Unwilling or unable to discontinue use of nonsteroidal anti-inflammatory drugs (NSAIDs) within 7 days of scheduled surgery, or medical marijuana or cannabidiol (CBD) within 10 days
  3. Total or partial knee arthroplasty in the contralateral knee < 6 months prior to study surgery
  4. Participation or scheduled participation in another clinical study involving an investigational drug or device within 30 days before screening or during study follow-up
  5. Active or past infection in the index knee
  6. Documented osteonecrosis of the index knee within previous 12 months
  7. Other planned major surgery within 12 months of study surgery
  8. Had a malignancy in the last year, except for non-metastatic basal cell or squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix
  9. Diagnosis of skin disorders including psoriasis, vascular insufficiency ulcers, and chronic venous stasis
  10. History of coronary or vascular stent placed within 3 months
  11. Suspected opioid abuse in the last 12 months with a score exceeding 5 on the DAST-10 questionnaire, and/or taking opioids on most days in the past three months, and currently taking >120 mg morphine equivalent dose (MED) at least 5 days per week in the month prior to screening
  12. Current medical diagnosis or subject-reported seizure disorder
  13. Current peripheral neuropathy
  14. History of complex regional pain syndrome (CRPS)
  15. Diagnosis of clinically significant liver hepatic and/or renal abnormalities within previous 2 years
  16. Diagnosis of diabetes with HbA1c ≥7%
  17. Current inflammatory arthritides (e.g., rheumatoid arthritis, lupus erythematosus, ankylosing spondylitis, psoriatic arthritis), or traumatic bone injuries within 12 months before scheduled surgery, except for clinically stable/non-active gout that does not affect the knee and does not interfere with walking
  18. Treatment with immunosuppressants, antipsychotics, anticholinergics, or anticonvulsants within 1 month of intervention (antipsychotic stable dosage established for >30 days will be allowed)
  19. Current or historical evidence of any clinically significant disease or condition, especially cardiovascular, pulmonary, or neurological
  20. Participation in active or pending personal injury or workers' compensation litigation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04860635

Layout table for location information
United States, Colorado
Panorama Orthopedics & Spine Center
Denver, Colorado, United States, 80401
United States, Texas
Endeavor Clinical Trials
San Antonio, Texas, United States, 78229
Sponsors and Collaborators
Arthritis Innovation Corporation
Layout table for investigator information
Principal Investigator: Jared Foran, MD Panorama Orthopedics & Spine Center
Layout table for additonal information
Responsible Party: Arthritis Innovation Corporation Identifier: NCT04860635    
Other Study ID Numbers: 100-CIP03-P
First Posted: April 27, 2021    Key Record Dates
Last Update Posted: February 24, 2022
Last Verified: July 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Arthritis Innovation Corporation:
total knee arthroplasty
postoperative pain
multimodal analgesia
Additional relevant MeSH terms:
Layout table for MeSH terms
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action